Table 2.

Univariate and multivariate Cox regression of clinical characteristics and inflammatory biomarkers in 153 esophageal squamous cell carcinoma patients

Variables	Three years’ OS
	Univariate analysis		Multivariate analysis
	HR (95% CI)	p-value	Adjusted HR (95% CI)a	p-value
Gender (male)	1.787 (0.927–3.445)	0.083	–	–
Age (≥ 60 years)	1.017 (0.663–1.559)	0.940	–	–
Tobacoo (yes)	1.093 (0.727–1.643)	0.670	–	–
Alcohol (yes)	1.065 (0.703–1.614)	0.767	–	–
Hypertension (yes)	1.102 (0.482–2.522)	0.818	–	–
Diabetes (yes)	20.837 (0.042–10283.099)	0.337	–	–
Tumor stage (III)	1.460 (0.945–2.256)	0.088	–	–
Depth of invasion (T3)	2.523 (1.366–4.661)	0.003	3.622 (1.591–8.242)	0.002
Lympth node (yes)	1.086 (0.717–1.645)	0.098	–	–
Differentiation (poor)	2.041 (1.008–4.131)	0.047	1.579 (0.641–3.889)	0.321
Tumor size (≥ 4 cm)	1.413 (0.910–2.193)	0.124	–	–
Radio-chemotherapy (yes)	1.444 (0.812–2.566)	0.211	–	–
NLR (≥ 2.1)	1.495 (0.967–2.311)	0.070	–	–
PLR (≥ 145.9)	1.640 (1.085–2.479)	0.019	1.964 (1.129–3.415)	0.017
LMR (< 2.3)	2.066 (1.166–3.663)	0.013	1.445 (0.669–3.115)	0.349
dNLR (≥ 4.3)	2.387 (1.515–3.761)	< 0.001	2.338 (1.626–5.308)	< 0.001
Fib (≥ 3.2 mg/dL)	1.886 (1.242–2.866)	0.003	2.148 (1.229–3.753)	0.007
Alb (< 38.2 g/L)	1.969 (1.266–3.058)	0.003	2.398 (1.342–4.273)	0.003
AFR (< 9.3)	1.953 (1.175–3.247)	0.010	2.381 (1.152–4.926)	0.019

OS overall survival, HR hazard ratio, CI confidence interval, NLR neutrophil to lymphocytes ratio, dNLR derived neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, LMR lymphocyte to monocyte ratio, Fib fibrinogen, Alb albumin, AFR albumin to fibrinogen ratio

^aAdjusted by sex, age, alcohol, tobacco, hypertension, diabetes, radio-chemotherapy, tumor size, tumor grade and tumor stage